上海健磨信息技术股份有限公司董事会 关于独立董事独立性自查情况的专项意见 过去12个月内,本公司独立董事未在公司担任除独立董事 以外的任何职务,也未在公司主要股东公司担任任何职务,与 公司以及主要股东之间不存在利害关系或其他可能妨碍其进行 独立客观判断的关系，符合《上市公司独立董事管理办法》、 《上海证券交易所上市公司自律监管指引第1号 -- 规范运作》 中规定的独立董事独立性的相关要求,不存在影响其独立性的 情形。 上海健磨信息技术股份 根据《上市公司独立董事管理办法》《上海证券交易所上市 公司自律监管指引第1号 -- 规范运作》等法律法规、规范性文 件的要求,上海健磨信息技术股份有限公司董事会(简称"本公 司")董事会逐项对照独立性规定,核查了本公司独立董事的独 立性,结合独立董事的任职经历及其签署的独立性自查文件, 出具专项意见如下: ...

根据《企业会计准则》以及公司会计政策的相关规定，为真实、客观地反映 公司 2024 年的财务状况和经营成果，基于谨慎性原则，公司对截至 2024 年 12 月 31 日存在减值迹象的相关资产计提减值准备。2024 年度确认的资产减值损失 和信用减值损失总额为 4,961,600.15 元。主要如下： 单位：元 | 序号 | 项目 | 本期发生额 | | --- | --- | --- | | 一 | 信用减值损失 | 2,891,600.15 | | 其中： | 应收账款坏账损失 | 2,788,200.15 | | | 长期应收款坏账损失 | 103,400.00 | | 二 | 资产减值损失 | 2,070,000.00 | | 其中： | 合同资产减值损失 | 2,070,000.00 | | 合计 | | 4,961,600.15 | 二、计提依据 本公司对以摊余成本计量的金融资产、以公允价值计量且其变动计入其他综 合收益的金融资产（债务工具）和财务担保合同等以预期信用损失为基础进行减 值会计处理。 证券代码：605186 证券简称： 健麾信息 公告编号：2025-011 上海健麾信息技术股份有限公司 ...

证券代码：605186 证券简称：健麾信息 公告编号：2025-006 上海健麾信息技术股份有限公司 第三届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海健麾信息技术股份有限公司（以下简称"公司"）第三届监事会第六次 会议于 2025 年 4 月 28 日上午以现场结合通讯方式召开，会议通知及相关材料已 于 2025 年 4 月 17 日通过电子邮件方式送达各位监事。本次会议应出席监事 3 人，实际出席监事 3 人，全体监事均亲自出席了本次会议。本次会议由公司监事 会主席刘羽洋先生主持。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以下简 称"《公司法》"）等法律法规和《公司章程》等有关规定。 监事会认为：2024 年度，监事会认真履行工作职责，审慎行使《公司章程》 和股东大会赋予的职权，结合公司实际经营需要，共召开三次监事会会议，会议 的通知、召开、表决程序符合《公司法》、《公司章程》、《监事会议事规则》等相 关规定。该工作报告真实、准确、完整地体现了公 ...

证券代码：605186 证券简称：健麾信息 公告编号：2025-005 上海健麾信息技术股份有限公司 第三届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海健麾信息技术股份有限公司（以下简称"公司"）第三届董事会第六次 会议于 2025 年 4 月 28 日上午以现场结合通讯方式召开，会议通知及相关材料已 于 2025 年 4 月 17 日通过电子邮件方式送达各位董事。本次会议应出席董事 8 人，实际出席董事 8 人，全体董事均亲自出席了本次会议。本次会议由公司董事 长戴建伟先生主持，公司全体监事和高级管理人员列席。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以下简 称"《公司法》"）等法律法规和《公司章程》等有关规定。 二、董事会会议审议情况 经与会董事认真审议并投票表决，会议形成了以下决议： 1、审议通过《关于〈2024 年度总经理工作报告〉的议案》 根据《公司法》、《中华人民共和国证券法》（以下简称"《证券法》"）、《公司 章程》及《经理工作细则》等 ...

证券代码：605186 证券简称： 健麾信息 公告编号：2025-007 上海健麾信息技术股份有限公司 关于 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例，每股转增比例： A股每股派发现金红利0.00元 每股派送红股0股，每股转增0股 公司未触及《上海证券交易所股票上市规则》第9.8.1条第一款第（八） 项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经立信会计师事务所（特殊普通合伙）审计，截至2024年12月31日，公司母 公司报表中期末未分配利润为人民币233,162,211.41元。经董事会决议，公司2024 年度不进行现金分红，不送红股，不进行资本公积转增股本和其他形式的利润分 配，未分配利润结转以后年度分配，具体如下： 公司拟向全体股东每股派发现金红利0.00元。截至2024年12月31日，公司总 股本136, 000,000股，以2024年12月31日的公司总股本为基数，向全体股东每10 股派发现金红利0元 ...

国信证券股份有限公司关于 上海健麾信息技术股份有限公司 2024 年度 募集资金存放与使用情况的专项核查意见 国信证券股份有限公司（以下简称"保荐机构"）作为上海健麾信息技术股 份有限公司（以下简称"健麾信息"或"公司"）首次公开发行股票并上市的保 荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规 则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上海证券交易 所上市公司自律监管指南第 1 号——公告格式》等有关规定，对健麾信息 2024 年度募集资金存放与使用情况进行了审慎核查，具体核查情况如下： 一、募集资金基本情况 根据公司2019年第二次临时股东大会决议，并经中国证券监督管理委员会出 具的《关于核准上海健麾信息技术股份有限公司首次公开发行股票的批复》（证 监许可[2020]3211号），公司于2020年12月首次公开发行人民币普通股（A股） 34,000,000股。公司每股发行价格为人民币14.20元，募集资金总额为人民币 482,800,000.00元，扣除承销、保荐费用人民币27,988, ...

上海健麾信息技术股份有限公司全体股东： 我们接受委托，对后附的上海健麾信息技术股份有限公司（以下 简称"健麾信息"）2024年度募集资金存放与使用情况专项报告（以下 简称"募集资金专项报告"）执行了合理保证的鉴证业务。 上海健麾信息技术股份有限公司 鉴证报告 二〇二四年度 关于上海健麾信息技术股份有限公司 2024年度募集资金存放与使用情况专项报告的 鉴证报告 信会师报字[2025]第ZA12577号 一、董事会的责任 健麾信息董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《上海证券交易所 上市公司自律监管指引第1号——规范运作》以及《上海证券交易所 上市公司自律监管指南第1号——公告格式》的相关规定编制募集资 金专项报告。这种责任包括设计、执行和维护与募集资金专项报告编 制相关的内部控制，确保募集资金专项报告真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 三、工作概述 我们按照《中国注册会计 ...

Financial Performance - The net profit attributable to the parent company's shareholders for 2024 is CNY 32,520,676.27[6]. - In 2024, the company's operating revenue increased by 3.51% year-on-year to CNY 318,349,489.92, while net profit attributable to shareholders decreased by 45.80% to CNY 32,520,676.27[24]. - The net profit excluding non-recurring gains and losses dropped by 62.07% year-on-year to CNY 17,145,709.78, reflecting significant challenges in the domestic market[26]. - Basic and diluted earnings per share fell by 45.45% to CNY 0.24, while the basic earnings per share after excluding non-recurring gains and losses decreased by 60.61% to CNY 0.13[25]. - The weighted average return on equity decreased by 2.76 percentage points to 3.06%, indicating a decline in profitability[25]. - The total assets at the end of 2024 reached CNY 1,466,011,224.89, an increase of 11.33% compared to the previous year[24]. - The net cash flow from operating activities improved significantly, reaching CNY 17,677,554.78, compared to a negative cash flow in 2023[24]. - The company reported a significant increase in revenue, achieving a total of $500 million for the quarter, representing a 25% year-over-year growth[149]. Dividend Policy - The company plans not to distribute cash dividends, issue bonus shares, or increase capital reserves for 2024[6]. - The company will not distribute cash dividends or issue new shares for 2024, opting to retain profits for R&D and business expansion[175]. - The company’s cash dividend ratio for the year is 0.00%, reflecting a strategy focused on long-term growth and investment in R&D[175]. - The cumulative cash dividend amount over the last three accounting years was RMB 25,840,000.00, representing a cash dividend ratio of 37.23% of the average annual net profit[180]. - There were no cash dividends or stock bonuses declared for the current reporting period[179]. Operational Efficiency - The company has strengthened its operational capabilities through strict budget execution and lean production management, improving overall operational efficiency[37]. - The company reported a significant improvement in accounts receivable management, leading to better cash collection compared to previous years[26]. - The net cash flow from operating activities improved significantly, reaching 17.68 million yuan, attributed to better accounts receivable management[74]. - The company has implemented intelligent drug management projects in over 1,000 hospitals across 31 provinces, enhancing brand recognition[69]. Market Expansion and Strategy - The company is actively expanding into emerging businesses such as intelligent distribution centers and logistics with mobile robots, although profit margins in these areas still need improvement[26]. - The company plans to continue focusing on market expansion and new technology development to enhance future performance[26]. - The company established a joint venture in Riyadh, Saudi Arabia, with Ajlan & Bros to promote its products in the Middle East and North Africa markets, aiming to enhance the digitalization and automation of the healthcare industry[34]. - The company is actively exploring the pharmaceutical retail market, planning to replicate the "smart pharmacy" model nationwide, integrating various product categories beyond pharmaceuticals[35]. - The company aims to expand its "to-G" business and overseas markets, particularly in the Middle East, Southeast Asia, and Europe, to increase its international influence and revenue share[123]. Research and Development - The company is increasing R&D investments to develop customized product solutions for overseas markets, enhancing its international brand influence and competitiveness[36]. - The R&D team has nearly 20 years of experience, enabling strong technical innovation and product development capabilities[65]. - The company plans to enhance its R&D capabilities and product development, focusing on market-oriented strategies and advanced technologies such as machine vision and deep learning[122]. - The company emphasizes the importance of R&D for maintaining competitive advantages in the pharmaceutical management sector[54]. Governance and Compliance - The report includes a standard unqualified audit opinion from Lixin Certified Public Accountants[5]. - The company emphasizes the importance of the accuracy and completeness of the financial report[5]. - The internal control system was evaluated as effective with no significant deficiencies reported for financial reporting[183]. - The company has not reported any major differences in governance compared to regulations set by the China Securities Regulatory Commission[142]. Risks and Challenges - The company has described potential risks in the report, urging investors to pay attention[9]. - The overall economic environment remains challenging, impacting the company's performance and necessitating ongoing strategic adjustments[33]. - In 2024, the company faced challenges due to delayed payments and bad debt provisions, resulting in performance not meeting expectations[33]. Shareholder Commitments - The company commits to not transferring or entrusting the management of shares held before the issuance for 36 months post-listing[196]. - The actual controller, Dai Jianwei, and the actual controller, Sun Dong, have both committed to not transferring shares for 36 months post-IPO[193]. - The commitments include provisions for adjustments in case of changes to regulations regarding share transfers[193]. - The company has ensured that all relevant legal and regulatory requirements are being adhered to in relation to share transfers and commitments[195].

Financial Performance - The company's operating revenue for Q1 2025 was ¥77,062,237.46, representing a 116.27% increase compared to ¥35,633,143.76 in the same period last year[4]. - Net profit attributable to shareholders decreased by 34.65% to ¥3,426,112.19 from ¥5,242,315.57 year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 30.93% to ¥3,293,843.93 compared to ¥4,768,546.05 in the previous year[4]. - The basic earnings per share decreased by 25.00% to ¥0.03 from ¥0.04 in the same period last year[6]. - Operating profit for Q1 2025 was ¥2,989,535.61, slightly down from ¥3,059,665.14 in Q1 2024, indicating a decrease of 2.3%[16]. - Net profit for Q1 2025 was ¥1,421,430.66, a decline of 39.7% from ¥2,357,351.02 in Q1 2024[16]. - Earnings per share for Q1 2025 were ¥0.03, compared to ¥0.04 in Q1 2024, reflecting a 25% decrease[17]. - The company reported a total operating cost of ¥70,665,174.04 for Q1 2025, up 105.6% from ¥34,358,791.33 in Q1 2024[15]. - The company recorded an investment loss of ¥3,135,299.41 in Q1 2025, slightly higher than the loss of ¥3,068,294.00 in Q1 2024[16]. Cash Flow and Assets - The net cash flow from operating activities improved to -¥28,754,383.31 from -¥64,638,160.26 year-on-year, indicating a reduction in cash payments for goods[4][8]. - Cash flow from operating activities for Q1 2025 was negative at -¥28,754,383.31, an improvement from -¥64,638,160.26 in Q1 2024[21]. - The company reported a decrease in cash and cash equivalents to RMB 80,918,614.87 from RMB 123,838,936.62, a decline of about 34.6%[11]. - The beginning balance of cash and cash equivalents was $121,835,498.45, down from $233,701,032.61 year-over-year[22]. - The ending balance of cash and cash equivalents stood at $80,317,242.86, a decrease from $153,157,170.00 compared to the previous period[22]. - Total assets at the end of the reporting period were ¥1,473,615,747.45, a slight increase of 0.52% from ¥1,466,011,224.89 at the end of the previous year[6]. - The company's total assets as of March 31, 2025, amount to RMB 1,473,615,747.45, an increase from RMB 1,466,011,224.89 at the end of 2024[12]. - Current assets total RMB 735,762,983.90, slightly down from RMB 748,323,890.23[12]. - Accounts receivable increased to RMB 463,092,641.05 from RMB 411,897,556.09, reflecting a growth of approximately 12.4%[11]. - Inventory decreased to RMB 71,694,634.53 from RMB 99,691,956.05, a decline of about 28.1%[12]. - Total liabilities increased to RMB 311,614,976.77 from RMB 305,431,884.87, indicating a rise of approximately 2.1%[13]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,423[10]. - The largest shareholder, Dai Jianwei, holds 57,113,219 shares, representing 42.00% of total shares[10]. - The number of shares held by the top 10 shareholders remains unchanged, indicating stability in shareholder structure[11]. - The company has no significant changes in its transfer and lending business, maintaining a stable operational environment[11]. Business Strategy and Market Conditions - The company is actively expanding into emerging businesses such as intelligent static distribution centers and logistics with mobile robots, although profit margins in these areas still need improvement[8]. - The company reported a significant impact from the global economic slowdown and reduced domestic market demand, affecting overall profitability[8]. - The company plans to focus on market expansion and new product development in the upcoming quarters[15]. - Research and development expenses for Q1 2025 were ¥4,821,605.40, down 27% from ¥6,600,012.24 in Q1 2024[15].